Last reviewed · How we verify
NCT06364527
Use of Aptar Digital Health's Respiratory Disease Management Platform for Asthma
NA trial testing Aptar Digital Health respiratory disease management platform in Asthma Chronic in 94 participants. Completed in 27 January 2026.
27 January 2026
Quick facts
| Lead sponsor | CoheroHealth |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | health services research |
| Enrollment | 94 |
| Start date | 18 July 2024 |
| Primary completion | 27 January 2026 |
| Estimated completion | 27 January 2026 |
| Sites | 1 location across United Kingdom |
Drugs / interventions tested
- Aptar Digital Health respiratory disease management platform
Conditions studied
- Asthma Chronic — all drugs for Asthma Chronic →
Sponsor
CoheroHealth — full company profile →
Who can join
16 and older, any sex, with Asthma Chronic. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The United Kingdom has a high prevalence of asthma (over 12%) and some of the worst health outcomes in Europe. The management of respiratory disease and associated patient outcomes has long been an area of focus and improvement for the National Health Service. With the advancement of digital health technology, there is the potential to transform patient care and improve outcomes. The Aptar Digital Health respiratory disease management platform, a digital therapeutic will be utilized to determine its value and how it supports: i) asthma patient engagement and facilitates communication between patients and providers to accelerate medication adherence; ii) asthma control through the use of the Asthma Control Questionnaire-5. In addition, spirometry and fractioned exhaled nitric oxide will be utilized during the study to validate and enhance current National Institute for Health and Care Excellence guidelines.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06364527
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Asthma Chronic
Currently open trials in the same condition.
- NCT06273072 — Metformin IN Asthma for Overweight and Obese Individuals (MINA) · Phase 2 · recruiting
- NCT06377345 — Remote Patient Monitoring Solution for Chronic Respiratory Disease Management · NA · recruiting
- NCT05572177 — Feasibility of a Smartphone Application for Asthma Self-management · NA · recruiting
Other CoheroHealth trials
Trials by the same sponsor.
- NCT03103880 — Assessing the Use of Mobile Technology in Adult Asthma Patients · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06364527 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CoheroHealth
- Last refreshed: 24 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06364527.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing